Bengaluru‑based CrisprBits closed $3 million in pre‑Series A financing to commercialize its PathCrisp CRISPR diagnostic platform and accelerate development of a CRISPR‑driven strain engineering platform. The round was led by Spectrum Impact and included founder and family‑office participation. CrisprBits plans to scale manufacturing for human, food‑safety and animal health tests and to expand PathCrisp into Africa and Latin America within six months. The company also aims to advance EdiCrisp — an end‑to‑end gene‑editing solution — and CurieCrisp for preclinical therapeutics. The raise underscores continued investor appetite for affordable CRISPR diagnostics and regional players building end‑to‑end capabilities for global markets.